ConductScience.org, home

Paper978134

Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.

Medicus RG and 2 others. J Exp Med, 1976. Cited by 193 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. Papers, record 978134. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/978134

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
PubMed
Journal
J Exp Med
PubMed
Year
1976
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
193
iCite
Relative citation ratio, by iCite
4.53
iCite
Revised in PubMed
2019-05-08
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Medicus RGR G
2Götze OO
3Müller-Eberhard HJH J

Source PubMed

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Complement C3Major topic
Complement C5Major topic
Complement System ProteinsMajor topic
EsterasesMajor topic
ProperdinMajor topic
Protein PrecursorsMajor topic
Animals
Cell Membrane
Erythrocytes
Humans
In Vitro Techniques
Sheep

Source PubMed

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
114,316,946ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.J Exp Med1965https://conductscience.org/library/papers/14316946PubMed
26,019,133Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.J Exp Med1967https://conductscience.org/library/papers/6019133PubMed
362,010Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.J Exp Med1976https://conductscience.org/library/papers/62010PubMed
41,185,108Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.J Exp Med1975https://conductscience.org/library/papers/1185108PubMed
54,130,153The utilization of properdin in the alternate pathway of complement activation: isolation of properdin convertase.J Immunol1974https://conductscience.org/library/papers/4130153PubMed
64,111,773C3 proactivator convertase and its mode of action.J Exp Med1972https://conductscience.org/library/papers/4111773PubMed
74,160,044A method of trace iodination of proteins for immunologic studies.Int Arch Allergy Appl Immunol1966https://conductscience.org/library/papers/4160044PubMed
84,202,731Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement.J Exp Med1973https://conductscience.org/library/papers/4202731PubMed
94,207,623A serum factor in chronic hypocomplementemic hephritis distinct from immunoglobulins and activating the alternate pathway of complement.J Exp Med1974https://conductscience.org/library/papers/4207623PubMed
102,647Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement.J Exp Med1976https://conductscience.org/library/papers/2647PubMed
114,477,550Studies on the sub-unit structure of human properdin.Immunochemistry1974https://conductscience.org/library/papers/4477550PubMed
124,808,709The role of properdin in the alternate pathway of complement activation.J Exp Med1974https://conductscience.org/library/papers/4808709PubMed
134,795,621
The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
J Immunol1973https://conductscience.org/library/papers/4795621PubMed
144,818,459Isolation and characterization of the proenzyme form of the C1r subunit of the first complement component.J Immunol1974https://conductscience.org/library/papers/4818459PubMed
155,058,233Molecular analysis of the membrane attack mechanism of complement.J Exp Med1972https://conductscience.org/library/papers/5058233PubMed
165,329,367A molecular concept of immune cytolysis.Arch Pathol1966https://conductscience.org/library/papers/5329367PubMed
17808,993Inhibition of complement-derived enzymes.Ann N Y Acad Sci1975https://conductscience.org/library/papers/808993PubMed
181,059,108Properdin: initiation of alternative complement pathway.Proc Natl Acad Sci U S A1975https://conductscience.org/library/papers/1059108PubMed
191,249,415Purification of the sixth and seventh component of human complement without loss of hemolytic activity.J Immunol1976https://conductscience.org/library/papers/1249415PubMed
201,165,475Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.J Exp Med1975https://conductscience.org/library/papers/1165475PubMed

See all 22 references

Cited by74

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 193 citations.

PMIDTitleJournalYearIn PapersSource
42,131,334Properdin deficiency or anti-properdin treatment ameliorates disease in the C3 gain-of-function mouse model of atypical haemolytic uraemic syndrome.Front Immunol2026https://conductscience.org/library/papers/42131334PubMed
41,159,389Shaping Tumor Microenvironment by Amplifying the Complement Cascade for Improved Immune Response in Pancreatic Cancer Model.Mol Cancer Ther2026https://conductscience.org/library/papers/41159389PubMed
40,904,461The complement system in human pregnancy and preeclampsia.Front Immunol2025https://conductscience.org/library/papers/40904461PubMed
36,853,837A Monoclonal Antibody That Provides a Model for C3 Nephritic Factors.Monoclon Antib Immunodiagn Immunother2023https://conductscience.org/library/papers/36853837PubMed
36,713,423A novel assay that characterizes properdin function shows neutrophil-derived properdin has a distinct oligomeric distribution.Front Immunol2022https://conductscience.org/library/papers/36713423PubMed
35,517,827Mathematical Modeling of Complement Pathway Dynamics for Target Validation and Selection of Drug Modalities for Complement Therapies.Front Pharmacol2022https://conductscience.org/library/papers/35517827PubMed
34,671,342Modulation of the Complement System by Neoplastic Disease of the Central Nervous System.Front Immunol2021https://conductscience.org/library/papers/34671342PubMed
33,801,255The Brilliance of Borrelia: Mechanisms of Host Immune Evasion by Lyme Disease-Causing Spirochetes.Pathogens2021https://conductscience.org/library/papers/33801255PubMed
33,542,722Prognostic Value of Complement Properdin in Cancer.Front Immunol2020https://conductscience.org/library/papers/33542722PubMed
33,329,546Preparing for Life: Plasma Proteome Changes and Immune System Development During the First Week of Human Life.Front Immunol2020https://conductscience.org/library/papers/33329546PubMed
32,909,942Soluble collectin-12 mediates C3-independent docking of properdin that activates the alternative pathway of complement.Elife2020https://conductscience.org/library/papers/32909942PubMed
32,274,388Regulation of anti-microbial autophagy by factors of the complement system.Microb Cell2020https://conductscience.org/library/papers/32274388PubMed
31,736,953Urinary Properdin and sC5b-9 Are Independently Associated With Increased Risk for Graft Failure in Renal Transplant Recipients.Front Immunol2019https://conductscience.org/library/papers/31736953PubMed
31,552,043Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.Front Immunol2019https://conductscience.org/library/papers/31552043PubMed
31,214,159C3-Glomerulopathy Autoantibodies Mediate Distinct Effects on Complement C3- and C5-Convertases.Front Immunol2019https://conductscience.org/library/papers/31214159PubMed
30,487,789Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.Front Immunol2018https://conductscience.org/library/papers/30487789PubMed
30,141,176The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?Pediatr Nephrol2019https://conductscience.org/library/papers/30141176PubMed
30,135,690Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.Front Immunol2018https://conductscience.org/library/papers/30135690PubMed
29,954,621Properdin: A multifaceted molecule involved in inflammation and diseases.Mol Immunol2018https://conductscience.org/library/papers/29954621PubMed
29,167,939The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?Semin Immunopathol2018https://conductscience.org/library/papers/29167939PubMed

See all 74 cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/978134

GET https://conductscience.org/api/papers/v1/978134/references?page=2